Two patients with rheumatoid arthritis (RA) 
Introduction

Recently, significant progress has been made in the understanding of cellular and molecular pathways associated with auto-immune diseases including rheumatoid arthritis (RA) (1). This has led to the development of new specific therapeutic agents targeting pro-inflammatory cytokines such as tumor necrosis factor α (TNFα) or IL-1β. Infliximab is a chimeric monoclonal antibody that strongly binds to TNFα and neutralizes its biological activity by inhibiting binding to its receptors. Infliximab is now widely used for the treatment of refractory RA, Crohn's disease (CD) or psoriasis with obvious clinical benefit. However, several studies have reported that anti-TNFα therapy is associated with a high risk of serious infectious complications such as bacterial infections, tuberculosis and fungal infections
. Post marketing surveillance in Japan has identified that 0.33 percent of RA patients receiving infliximab had developed tuberculosis (3) . Keane 
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F i g u r e 3 . Ch e s t CT i ma g e o f c a s e 2 o n a d mi s s i o n s h o we d d i f f u s e b i l a t e r a l g r o u n d g l a s s o p a c i t i e s
